Studies have demonstrated that mitofusin agonists can restore normal transport of mitochondria in the sciatic nerves of mice carrying the MFN2 Thr105Met mutation, suggesting a promising therapeutic approach for managing CMT2A.165. The gene discussed is MFN2; the disease is Charcot-Marie-Tooth disease type 2A1.